Animal models of antiretroviral prophylaxis for HIV prevention
JG García-Lerma, W Heneine - Current Opinion in HIV and AIDS, 2012 - journals.lww.com
JG García-Lerma, W Heneine
Current Opinion in HIV and AIDS, 2012•journals.lww.comAs human data from PrEP trials validate animal models or help fine tune them, it is expected
that these models will play increasingly important roles in PrEP development as the field
extends into new drug classes and combinations, episodic dosing, and novel long-acting
drug formulations. By providing both efficacy and pharmacologic information these models
can define correlates and mechanisms of protection, inform dose selection, and advance the
most promising PrEP candidates and dosing modalities.
that these models will play increasingly important roles in PrEP development as the field
extends into new drug classes and combinations, episodic dosing, and novel long-acting
drug formulations. By providing both efficacy and pharmacologic information these models
can define correlates and mechanisms of protection, inform dose selection, and advance the
most promising PrEP candidates and dosing modalities.
Summary
As human data from PrEP trials validate animal models or help fine tune them, it is expected that these models will play increasingly important roles in PrEP development as the field extends into new drug classes and combinations, episodic dosing, and novel long-acting drug formulations. By providing both efficacy and pharmacologic information these models can define correlates and mechanisms of protection, inform dose selection, and advance the most promising PrEP candidates and dosing modalities.
Lippincott Williams & Wilkins